"What" Series

What is LD50?

25 April 2024
3 min read

LD50 (median lethal dose) is a commonly used indicator in toxicology to describe the toxicity of toxic substances or radiation. It is defined as the minimum dose required to kill half of a group of a certain weight or age of animals within a certain time through a specified route of administration. The smaller the LD50 value, the stronger the toxicity of the exogenous chemical substance; conversely, the larger the LD50 value, the lower the toxicity.

Determining LD50 is important for evaluating the acute toxicity of chemical substances and comparing the relative toxicity of different substances. It can also be used to calculate the therapeutic index of drugs and provide a reference for selecting doses for subsequent repeated-dose toxicological studies. Furthermore, by comparing the LD50 values of different routes, information on bioavailability can be obtained.

It should be noted that the determination of LD50 has limitations, such as limited information, high variability, and being influenced by various factors, including animal species, strain, sex, and route of exposure. Therefore, when expressing LD50, the specific animal species and route of exposure should be specified, and LD50 should be calculated separately for male and female animals.

In toxicological studies, there are several methods for calculating LD50, including the visual probit method, weighted probit method (Bliss method), Karber method, and sequential method. Among these, the Bliss method is considered to be a relatively accurate method, but due to its complex calculation process, it is often used to validate and compare the accuracy of other calculation methods.

The determination of LD50 can help reduce problems caused by measuring extreme situations and reduce the number of required tests. However, LD50 is not the lethal dose for all test organisms: some may die at doses much lower than LD50, while others may survive at doses much higher than LD50.

In special cases, researchers may also measure indicators such as LD1 or LD99 (the dose that kills 1% or 99% of the test population). Additionally, two indicators related to LD50, LD50/30 and LD50/60, refer to the doses that kill half of the test population without treatment within 30 or 60 days, respectively, and these indicators are typically used to describe radiation toxicity.

Due to criticism from animal rights organizations, some countries have begun to ban or reduce LD50 testing on animals. The Organization for Economic Co-operation and Development (OECD) also abolished the requirement for oral toxicity testing in 2001 and recommended using alternative methods instead.

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

The Phase 3 LUNA 3 trial of Rilzabrutinib successfully achieved its main goal in treating immune thrombocytopenia
Latest Hotspot
3 min read
The Phase 3 LUNA 3 trial of Rilzabrutinib successfully achieved its main goal in treating immune thrombocytopenia
25 April 2024
The recent phase 3 LUNA 3 trial demonstrated that 400 mg of rilzabrutinib taken orally twice daily effectively achieved the primary goal of sustaining platelet response in adults with persistent or chronic immune thrombocytopenia.
Read →
FDA Approves ImmunityBio’s ANKTIVA® for BCG-Resistant Bladder Cancer
Latest Hotspot
3 min read
FDA Approves ImmunityBio’s ANKTIVA® for BCG-Resistant Bladder Cancer
25 April 2024
ImmunityBio Receives FDA Nod for ANKTIVA®, a Novel IL-15 Receptor Stimulator, for Treating BCG-Resistant Non-Muscle Invasive Bladder Cancer.
Read →
Neurogene to Present Early Results on NGN-401 Gene Therapy for Rett Syndrome at ASGCT Conference
Latest Hotspot
3 min read
Neurogene to Present Early Results on NGN-401 Gene Therapy for Rett Syndrome at ASGCT Conference
25 April 2024
Neurogene Set to Reveal NGN-401 Gene Therapy Safety Results from Early Stage Trial for Rett Syndrome during ASGCT Conference.
Read →
Adicet Bio Showcases Preclinical Readiness of ADI-270 for IND at 27th ASGCT Meeting
Latest Hotspot
3 min read
Adicet Bio Showcases Preclinical Readiness of ADI-270 for IND at 27th ASGCT Meeting
25 April 2024
Adicet Bio presents preclinical findings indicating IND preparedness for ADI-270 during a talk at the 27th Annual ASGCT Meeting.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.